Screening Platform

DIAGNOSTIC_TEST5 trials

Sponsors

SWOG Cancer Research Network, GlaxoSmithKline, Hoffmann-La Roche, University of Maia, Istituto Clinico Humanitas

Conditions

Bladder CancerFatigue IntensityNeoplasmsPreviously Treated Non-Small Cell Lung CancerProstate CancerSolid Tumors

Phase 2

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

RecruitingNCT03851445

SWOG Cancer Research NetworkPreviously Treated Non-Small Cell Lung Cancer

Start: 2019-02-06End: 2029-01-28Target: 10000Updated: 2026-05-18

Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials

TerminatedNCT05100316

GlaxoSmithKlineNeoplasms

Start: 2021-12-16End: 2022-10-04Updated: 2024-02-05

Screening Study for Participants With Malignant Tumors

CompletedNCT05419375

Hoffmann-La RocheSolid Tumors

Start: 2022-07-22End: 2025-09-03Updated: 2026-02-03

Unknown Phase

Influence of Acute Daily Workload Changes on Low-frequency Fatigue Morning Scores

Not yet recruitingNCT06704854

University of MaiaFatigue Intensity

Start: 2024-11-25End: 2025-01-15Target: 20Updated: 2024-11-26

DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy

Active, not recruitingNCT07265414

Istituto Clinico HumanitasBladder Cancer, Prostate Cancer

Start: 2021-01-01End: 2026-01-31Updated: 2025-12-04

Related Papers

A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC).

Journal of Clinical Oncology2023-06-015 citations

ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent <i>KRAS</i> G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2023-06-012 citations

A master screening study to determine biomarker status and trial eligibility for patients with malignant tumors.

Journal of Clinical Oncology2023-06-01